紫杉醇涂层球囊血管成形术治疗支架再狭窄中的股浅动脉——三年随访结果。

IF 0.7 4区 医学 Q4 PERIPHERAL VASCULAR DISEASE
Vascular and Endovascular Surgery Pub Date : 2023-10-01 Epub Date: 2023-03-22 DOI:10.1177/15385744231165877
Julio Cesar Peclat de Oliveira, Rossano Kepler Alvim Fiorelli, Ana Paula Rolim Maia Peclat, Lucas Maia Peclat de Oliveira, Rafael Oliveira, Sergio Quilici Belczac, Renato Santos Almeida, Marcelo Bellini Dalio, Edwaldo Edner Joviliano, Bianca Gutfilen
{"title":"紫杉醇涂层球囊血管成形术治疗支架再狭窄中的股浅动脉——三年随访结果。","authors":"Julio Cesar Peclat de Oliveira,&nbsp;Rossano Kepler Alvim Fiorelli,&nbsp;Ana Paula Rolim Maia Peclat,&nbsp;Lucas Maia Peclat de Oliveira,&nbsp;Rafael Oliveira,&nbsp;Sergio Quilici Belczac,&nbsp;Renato Santos Almeida,&nbsp;Marcelo Bellini Dalio,&nbsp;Edwaldo Edner Joviliano,&nbsp;Bianca Gutfilen","doi":"10.1177/15385744231165877","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In-stent restenosis remains a common and important complication after endovascular treatment of superficial femoral artery peripheral artery disease. It occurs in 14 to 35% of cases in 1 year and there is still no efficient treatment for this condition. Paclitaxel-coated balloons have shown promising results.</p><p><strong>Objective: </strong>Investigate the 3 year results of superficial femoral artery in-stent restenosis treated with paclitaxel-coated balloon angioplasty, using the Lutonix™ 035 device.</p><p><strong>Methods: </strong>We conducted a retrospective observational study with patients with symptomatic (Rutherford 2 to 5) superficial femoral artery in-stent restenosis, that were treated with paclitaxel-coated balloon angioplasty using the Lutonix™ 035 device, in a single center from January 2016 to December 2020. Duplex scan was used to follow the patients. Primary patency was obtained through Kaplan-Meier analysis. Mortality, and amputation rates were also evaluated.</p><p><strong>Results: </strong>105 patients were included. Two patients had technical failure and required an additional stent, and were thus excluded. 103 patients were analyzed. Primary patency was 91.26, 80.47, and 67.71%, respectively, in the first, second, and third year after the procedure. There were no deaths 30 days after the procedure. There were no major amputations during the 3 year follow-up.</p><p><strong>Conclusion: </strong>Paclitaxel-coated balloon angioplasty with the Lutonix™ 035 device was a safe and effective treatment to superficial femoral artery in-stent restenoses. The results were maintained along the 3 year follow-up.</p>","PeriodicalId":23530,"journal":{"name":"Vascular and Endovascular Surgery","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Superficial Femoral Artery in-Stent Restenosis Treated with Paclitaxel-Coated Balloon Angioplasty - Results of Three-Year Follow-Up.\",\"authors\":\"Julio Cesar Peclat de Oliveira,&nbsp;Rossano Kepler Alvim Fiorelli,&nbsp;Ana Paula Rolim Maia Peclat,&nbsp;Lucas Maia Peclat de Oliveira,&nbsp;Rafael Oliveira,&nbsp;Sergio Quilici Belczac,&nbsp;Renato Santos Almeida,&nbsp;Marcelo Bellini Dalio,&nbsp;Edwaldo Edner Joviliano,&nbsp;Bianca Gutfilen\",\"doi\":\"10.1177/15385744231165877\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In-stent restenosis remains a common and important complication after endovascular treatment of superficial femoral artery peripheral artery disease. It occurs in 14 to 35% of cases in 1 year and there is still no efficient treatment for this condition. Paclitaxel-coated balloons have shown promising results.</p><p><strong>Objective: </strong>Investigate the 3 year results of superficial femoral artery in-stent restenosis treated with paclitaxel-coated balloon angioplasty, using the Lutonix™ 035 device.</p><p><strong>Methods: </strong>We conducted a retrospective observational study with patients with symptomatic (Rutherford 2 to 5) superficial femoral artery in-stent restenosis, that were treated with paclitaxel-coated balloon angioplasty using the Lutonix™ 035 device, in a single center from January 2016 to December 2020. Duplex scan was used to follow the patients. Primary patency was obtained through Kaplan-Meier analysis. Mortality, and amputation rates were also evaluated.</p><p><strong>Results: </strong>105 patients were included. Two patients had technical failure and required an additional stent, and were thus excluded. 103 patients were analyzed. Primary patency was 91.26, 80.47, and 67.71%, respectively, in the first, second, and third year after the procedure. There were no deaths 30 days after the procedure. There were no major amputations during the 3 year follow-up.</p><p><strong>Conclusion: </strong>Paclitaxel-coated balloon angioplasty with the Lutonix™ 035 device was a safe and effective treatment to superficial femoral artery in-stent restenoses. The results were maintained along the 3 year follow-up.</p>\",\"PeriodicalId\":23530,\"journal\":{\"name\":\"Vascular and Endovascular Surgery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vascular and Endovascular Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/15385744231165877\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/3/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular and Endovascular Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15385744231165877","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/3/22 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

背景:支架内再狭窄仍然是股浅动脉-外周动脉疾病血管内治疗后常见且重要的并发症。在一年内,14%至35%的病例会发生这种情况,目前还没有有效的治疗方法。紫杉醇涂层气球已经显示出有希望的结果。目的:研究应用紫杉醇涂层球囊血管成形术治疗股浅动脉支架内再狭窄的3年疗效™ 035设备。方法:我们对有症状的(Rutherford 2-5)股浅动脉支架内再狭窄患者进行了一项回顾性观察研究,这些患者使用Lutonix™ 035设备,于2016年1月至2020年12月在单个中心。采用双重扫描对患者进行随访。主要通畅性通过Kaplan-Meier分析获得。死亡率和截肢率也进行了评估。结果:纳入105例患者。两名患者出现技术故障,需要额外的支架,因此被排除在外。对103例患者进行了分析。术后第一年、第二年和第三年的初次通畅率分别为91.26%、80.47%和67.71%。术后30天无死亡病例。在3年的随访中并没有发生大的截肢。结论:紫杉醇涂层的Lutonix球囊血管成形术™ 035装置是一种安全有效的治疗股浅动脉支架置入术的方法。结果在3年的随访中得以维持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Superficial Femoral Artery in-Stent Restenosis Treated with Paclitaxel-Coated Balloon Angioplasty - Results of Three-Year Follow-Up.

Background: In-stent restenosis remains a common and important complication after endovascular treatment of superficial femoral artery peripheral artery disease. It occurs in 14 to 35% of cases in 1 year and there is still no efficient treatment for this condition. Paclitaxel-coated balloons have shown promising results.

Objective: Investigate the 3 year results of superficial femoral artery in-stent restenosis treated with paclitaxel-coated balloon angioplasty, using the Lutonix™ 035 device.

Methods: We conducted a retrospective observational study with patients with symptomatic (Rutherford 2 to 5) superficial femoral artery in-stent restenosis, that were treated with paclitaxel-coated balloon angioplasty using the Lutonix™ 035 device, in a single center from January 2016 to December 2020. Duplex scan was used to follow the patients. Primary patency was obtained through Kaplan-Meier analysis. Mortality, and amputation rates were also evaluated.

Results: 105 patients were included. Two patients had technical failure and required an additional stent, and were thus excluded. 103 patients were analyzed. Primary patency was 91.26, 80.47, and 67.71%, respectively, in the first, second, and third year after the procedure. There were no deaths 30 days after the procedure. There were no major amputations during the 3 year follow-up.

Conclusion: Paclitaxel-coated balloon angioplasty with the Lutonix™ 035 device was a safe and effective treatment to superficial femoral artery in-stent restenoses. The results were maintained along the 3 year follow-up.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vascular and Endovascular Surgery
Vascular and Endovascular Surgery SURGERY-PERIPHERAL VASCULAR DISEASE
CiteScore
1.70
自引率
11.10%
发文量
132
审稿时长
4-8 weeks
期刊介绍: Vascular and Endovascular Surgery (VES) is a peer-reviewed journal that publishes information to guide vascular specialists in endovascular, surgical, and medical treatment of vascular disease. VES contains original scientific articles on vascular intervention, including new endovascular therapies for peripheral artery, aneurysm, carotid, and venous conditions. This journal is a member of the Committee on Publication Ethics (COPE).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信